Skip to content
Search

Latest Stories

RPS seeks extension of ‘protected learning time’ pilot

The Royal Pharmaceutical Society (RPS) has called for an extension of a new pilot on ‘protected learning time’ across Great Britain.

The 12-month pilot led by the Health Education and Improvement Wales (HEIW) will explore the value of three different models of protected learning time in community pharmacy.


“We’re calling for it to be replicated on a bigger scale in England and Scotland so more data can be collected on the approaches that most benefit pharmacists and to help support protected learning time for pharmacists to become reality across Great Britain,” said RPS director of pharmacy and member experience Robbie Turner.

The project will also consider mentor input and attendance at training during the pilot.

“Regular paid protected learning time should be standard practice for all pharmacists in all sectors, regardless of career stage,” Turner said.

For several years, pharmacists have been using their own time to acquire new skills that are essential to their role and service, which can increase stress level as they cannot ‘switch off’ after work, he added.

“Apart from professional advancement, protected learning time as a group can help with team-building and improving staff morale, which is essential to wellbeing, as well as improving services to patients,” Turner said.

Protected learning time will become more crucial in providing safe services to patients, as pharmacists these days are entering multi-disciplinary team and take on more clinical roles, he said.

More For You

Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less